Davis v. SMITHKLINE BEECHAM CLINICAL LABORATORIES, INC.

993 F. Supp. 897, 1998 U.S. Dist. LEXIS 2219, 1998 WL 88394
CourtDistrict Court, E.D. Pennsylvania
DecidedFebruary 26, 1998
DocketCIV. A. 98-0109
StatusPublished
Cited by4 cases

This text of 993 F. Supp. 897 (Davis v. SMITHKLINE BEECHAM CLINICAL LABORATORIES, INC.) is published on Counsel Stack Legal Research, covering District Court, E.D. Pennsylvania primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Davis v. SMITHKLINE BEECHAM CLINICAL LABORATORIES, INC., 993 F. Supp. 897, 1998 U.S. Dist. LEXIS 2219, 1998 WL 88394 (E.D. Pa. 1998).

Opinion

ORDER AND EXPLANATION

ANITA B. BRODY, District Judge.

This class action was filed in the Philadelphia Court of Common Pleas on December 5, 1997. The Complaint alleges violations of the Pennsylvania Unfair Trade Practices and Consumer Protection Act, fraud, negligence, and unjust enrichment, based on defendant SmithKline Beeeham Clinical Laboratories, Inc. (“SBCL”)’s alleged fraudulent billing for laboratory tests. The class plaintiff seeks to represent consists of “all persons or entities who, between January 1,1989 and December 30, 1996 (‘Class Period’), paid SBCL inflated fees or charges for clinical laboratory tests and were injured thereby (the ‘Class’).”

*898 SBCL removed the case to federal court pursuant to 28 U.S.C. § 1441. Plaintiff Arthur Davis (“Davis”) has now moved for a remand to state court. While the motion for remand in this case was pending, the Judicial Panel on Multidistrict Litigation entered an order transferring three related cases against SBCL, all alleging improper billing practices for clinical laboratory testing, to the Honorable Alfred V. Covello in the District of Connecticut for consolidated pretrial proceedings with three related actions already pending in the District of Connecticut. On February 18, 1998, the Panel entered a conditional transfer of the instant case to the District of Connecticut; this transfer will take effect on March 5,1998. Thus, currently before me is the Plaintiffs Motion for Remand.

Plaintiff argues that this ease should be remanded because there are no federal questions on the face of the Complaint. Plaintiffs Remand Mem. at 5. Defendant responds that some of the claims are completely preempted by the civil enforcement scheme of the Employee Retirement Income Security Act of 1974, 29 U.S.C. § 1001 et seq. (“ERISA”), because Davis and the class seek restitution of funds, including ERISA plan funds, paid to SBCL. Defendant’s Remand Mem. at 10-14. Plaintiff, however, asserts that none of the claims in the Complaint involve the enforcement provisions of ERISA, and, therefore, none of them are completely preempted. Plaintiffs Remand Mem. at 5.

In deciding whether this action should be remanded, I must resolve two inquiries: first, whether Davis’ complaint relies upon federal law as a ground for recovery, and, second, if it does not, whether it makes a claim that is “completely preempted” by federal law.

Ordinarily, whether a case is one “arising under” the Constitution, laws or treaties of the United States, and therefore properly removable to the district court is determined by the district court’s examination of a plaintiffs claims under the well-pleaded complaint rule. Dukes v. U.S. Healthcare, Inc., 57 F.3d 350, 353 (3d Cir.1995). The well-pleaded complaint rule requires that the federal question be presented on the face of the plaintiffs complaint. See Metropolitan Life Insurance Co. v. Taylor, 481 U.S. 58, 62, 107 S.Ct. 1542, 95 L.Ed.2d 55 (1987). Davis’ complaint seeks restitution for violations of the Pennsylvania Unfair Trade Practices and Consumer Protection Act, fraud, negligence, and unjust enrichment. In no instance does the complaint rely upon federal law. Therefore, I will have jurisdiction only if Davis’ claims fall into one of the narrow areas that Congress has decided to completely preempt. See Franchise Tax Bd. of Cal. v. Construction Laborers Vacation Trust for S. Cal., 463 U.S. 1, 23, 103 S.Ct. 2841, 77 L.Ed.2d 420 (1983) (preemptive force of a federal statute such as ERISA as to which complete preemption applies is so powerful as to displace entirely any state cause of action for a claim).

The doctrine of complete preemption apples only when the enforcement provisions of a federal statute create a federal cause of action vindicating the same interest that the plaintiffs state law cause of action seeks to vindicate and when there is affirmative evidence of a congressional intent to permit removal despite the plaintiffs exclusive relance on state law. Allstate Ins. Co. v. 65 Sec. Plan, 879 F.2d 90, 93 (3d Cir.1989). The Supreme Court has narrowly appled the complete preemption exception to only two federal statutes, one of which is ERISA. Metropolitan Life, 481 U.S. at 66.

For a state law claim to be completely preempted by ERISA, it must be a claim which falls within the scope of ERISA’s civil enforcement scheme, § 502(a). See Joyce v. RJR Nabisco Holdings Corp., 126 F.3d 166, 172 (3d Cir.1997). Section 502(a) provides, in pertinent part:

a civil action may be brought:
(3) by a participant, beneficiary, or fiduciary (A) to enjoin any act or practice which violates any provision of this subehapter or the terms of the plan, or (B) to obtain other appropriate equitable relef (i) to redress such violations or (1) to enforce any *899 provisions of this subchapter or the terms of the plan ...

29 U.S.C. § 1132(a)(3).

The instant case falls within the scope of ERISA § 502(a). Davis’ Complaint explicitly seeks redress on behalf of “those persons and entities who paid for clinical laboratory tests performed by SBCL, as self-insurers, co-insurers, patients or contributors to ERISA welfare benefit plans.” Complaint, ¶ 3. Therefore, the putative class includes, as class members, ERISA plan participants and beneficiaries, third party administrators or contract administrators for ERISA plans, as well as the plans themselves, because these entities paid SBCL bills for clinical laboratory tests. Complaint, ¶¶ 22-23. Although some members of the putative class may not be ERISA participants, beneficiaries, or fiduciaries, as the case stands before me, I have one representative, Davis, by whom to decide preemption, and Davis, by his own pleadings, is an ERISA plan participant and beneficiary. 1 Plaintiffs Remand Mem. at 2. (“The Plaintiff personally paid SBCL for certain clinical laboratory tests performed on him by SBCL. Payments were made by Plaintiff either as a co-pay, co-insurance or part of the deductible under his health insurance plan. Complaint, ¶4. Plaintiffs health insurance plan was provided by his employer (or former employer) as an ERISA qualified health and welfare benefit plan.”)

Furthermore, Davis seeks to vindicate the same interest that the ERISA civil enforcement provisions allows.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Coker v. Purdue Pharma Co.
314 F. Supp. 2d 777 (W.D. Tennessee, 2004)
Thompson v. Abbott Laboratories
309 F. Supp. 2d 165 (D. Massachusetts, 2004)
In Re Pharmaceutical Industry Average Wholesale Price Litigation
309 F. Supp. 2d 165 (D. Massachusetts, 2004)
Keenan v. Unum Provident Corp.
252 F. Supp. 2d 163 (E.D. Pennsylvania, 2003)

Cite This Page — Counsel Stack

Bluebook (online)
993 F. Supp. 897, 1998 U.S. Dist. LEXIS 2219, 1998 WL 88394, Counsel Stack Legal Research, https://law.counselstack.com/opinion/davis-v-smithkline-beecham-clinical-laboratories-inc-paed-1998.